The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation. The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product [...]
PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative therapeutic solutions in oncology to top European investors at the EIC Investor Day with CUF. The event took place in Lisbon (Portugal) on 29 and 30 November 2022, where the Company has presented in the ‘Biotech & Pharmaceuticals session’ its antibodies [...]
Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference [...]
PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second discussion panel "Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society" at ASEBIO Investors Day organized by Asociación Española de Bioempresas. The panel was moderated by Carolina Pola, Innovation Strategist at Kaudal, and included reference speakers of the innovation ecosystem [...]
Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.